Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Apr;12(4):e241-e242.
doi: 10.1016/S2352-3026(25)00010-9.

Fedratinib for patients with myelofibrosis - Authors' reply

Affiliations
Comment

Fedratinib for patients with myelofibrosis - Authors' reply

Claire N Harrison et al. Lancet Haematol. 2025 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CNH receives research funding from Bristol Myers Squibb, Constellation–Morphosys, and Novartis; consulting fees from Galecto, Geron, and GlaxoSmithKline; honoraria from AbbVie, AOP Health, Bristol Myers Squibb–Celgene, CTI BioPharma, Galacteo, Geron, Gilead, IMAGO, Janssen, Keros, Novartis, Promedior, Roche, Shire, and Sierra; is on a data safety monitoring board or advisory board for Galacteo and Keros; and in a leadership position at the European Hematology Association. PB is employed by and holds stock or stock options in Bristol Myers Squibb. J-JK receives consulting fees from AbbVie and GlaxoSmithKline; honoraria from AOP Health and Novartis; and is on a data safety monitoring board or advisory board for Bristol Myers Squibb and Incyte.

Comment on

  • Fedratinib for patients with myelofibrosis.
    Van Dijck R, Schnog JJ, Te Boekhorst P. Van Dijck R, et al. Lancet Haematol. 2025 Apr;12(4):e240. doi: 10.1016/S2352-3026(24)00398-3. Lancet Haematol. 2025. PMID: 40174994 No abstract available.

References

LinkOut - more resources